Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

60635

	registered interest
	date	09/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Parkinson's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to improve patient choice and reduce avoidable harm for people with advanced Parkinson's.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	199567
	answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>From April 2013, NHS England assumed responsibility for commissioning adult specialist neurosciences services, including the majority of services for patients with Parkinson's disease, with some being the responsibility of clinical commissioning groups.</p><p> </p><p>NHS England has advised that it does not routinely fund Duodopa (co-careldopa) for the treatment of Parkinson's disease. Clinicians can submit individual funding requests for this treatment on behalf of their patients as per NHS England's individual funding requests standard operating procedure, which is found at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/04/cp-04.pdf</p><p> </p><p>NHS England has advised that its individual funding request process is monitored against the standard operating procedure to ensure that referring clinicians are informed of outcomes in a timely manner.</p><p><strong> </strong></p><p>Treatments for Parkinson's are largely drug based and there is a choice of therapies available. <em> Parkinson's disease: Diagnosis and management in primary and secondary care</em>, published by the National Institute for Health and Care Excellence in 2006, makes it clear that communication with people with Parkinson's disease should be aimed towards empowering them to participate in the judgements and choices about their own care. With regard to decisions about the drugs available for treatment of the disease in its later stages, the guidance states that the patient preference should be taken into account, once they have been informed of the short- and long-term benefits and drawbacks of the different types of drugs available.</p><p> </p><p>To reduce avoidable harm, through the Mandate we have asked NHS England to make measurable progress by 2015 to embed a culture of patient safety in the NHS including through improved reporting of incidents. The NHS Outcomes Framework contains a range of indicators designed to measure progress in this area of care which will be relevant to patients with all conditions, including, Parkinson's disease.</p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 199571 question first answered 16/06/2014 13:35:35 answering member 1439 label Biography information for Norman Lamb
	tabling member	394 label Biography information for Mr Clive Betts

60636

	registered interest
	date	09/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Parkinson's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to prevent unnecessary delays in the prescription of Duodopa for people with Parkinson's.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	199571
	answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>From April 2013, NHS England assumed responsibility for commissioning adult specialist neurosciences services, including the majority of services for patients with Parkinson's disease, with some being the responsibility of clinical commissioning groups.</p><p> </p><p>NHS England has advised that it does not routinely fund Duodopa (co-careldopa) for the treatment of Parkinson's disease. Clinicians can submit individual funding requests for this treatment on behalf of their patients as per NHS England's individual funding requests standard operating procedure, which is found at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/04/cp-04.pdf</p><p> </p><p>NHS England has advised that its individual funding request process is monitored against the standard operating procedure to ensure that referring clinicians are informed of outcomes in a timely manner.</p><p><strong> </strong></p><p>Treatments for Parkinson's are largely drug based and there is a choice of therapies available. <em> Parkinson's disease: Diagnosis and management in primary and secondary care</em>, published by the National Institute for Health and Care Excellence in 2006, makes it clear that communication with people with Parkinson's disease should be aimed towards empowering them to participate in the judgements and choices about their own care. With regard to decisions about the drugs available for treatment of the disease in its later stages, the guidance states that the patient preference should be taken into account, once they have been informed of the short- and long-term benefits and drawbacks of the different types of drugs available.</p><p> </p><p>To reduce avoidable harm, through the Mandate we have asked NHS England to make measurable progress by 2015 to embed a culture of patient safety in the NHS including through improved reporting of incidents. The NHS Outcomes Framework contains a range of indicators designed to measure progress in this area of care which will be relevant to patients with all conditions, including, Parkinson's disease.</p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 199567 question first answered 16/06/2014 13:35:35 answering member 1439 label Biography information for Norman Lamb
	tabling member	394 label Biography information for Mr Clive Betts

60637

	registered interest
	date	09/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Continuing Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that the Clinical Priorities Advisory Group takes account of evidence from (a) patients, (b) clinicians and (c) patient groups when making decisions on the availability of treatments for progressive conditions.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	199558
	answer	answer is ministerial correction date of answer 16/06/2014 answer text <p>NHS England has advised that the Clinical Priorities Advisory Group (CPAG) is an advisory group and not a decision making body. It considers policy and makes recommendations to the Directly Commissioned Services Committee who make the final decisions on NHS England's commissioning position.</p><p> </p><p>The Group's membership includes four Patient and Public Voice members and senior clinicians from NHS England. The policies that are presented to CPAG for consideration are developed by Clinical Reference Groups (CRGs) who are made up of patients, clinicians, and key stakeholders including patient groups. These members are involved in the development of policies.</p><p> </p><p>Prior to submission of any documents to CPAG, a two week stakeholder testing phase is undertaken where registered CRG stakeholders including clinicians, patients, and patient groups, as well as industry, have an opportunity to make comments. These are considered as well as the evidence base for the policy by CPAG.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 16/06/2014 14:32:45 answering member 3918 label Biography information for Jane Ellison
	tabling member	394 label Biography information for Mr Clive Betts